title: Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome.
abstract: CONCLUSIONS
  
  
  
  OBJECTIVE
  The benefits of fenofibrate, a peroxisome proliferator-activated receptor α agonist, against cardiovascular risk factors have been established. To clarify the underlying mechanisms of these benefits, we examined the effects of fenofibrate on insulin resistance, hypertension, inflammation, oxidative stress and coagulation markers in patients with metabolic syndrome.
  
  
  METHODS
  Eleven Japanese patients with metabolic syndrome underwent physical examinations and blood tests before and after treatment with fenofibrate 200 mg daily for 8 weeks.
  
  
  RESULTS
  Fenofibrate significantly decreased systolic blood pressure, pulse wave velocity, serum insulin, insulin resistance (calculated from the homeostasis model assessment), total cholesterol, triglyceride, remnant-like particles cholesterol, uric acid, D-dimer, fibrinogen, serum amyloid A/low-density lipoprotein (LDL) and apoA1/LDL levels. It also significantly increased levels of high molecular weight adiponectin, thrombomodulin and high-density lipoprotein cholesterol in these patients. Plasminogen activator inhibitor-1, C-reactive protein, fasting plasma glucose and thrombin-antithrombin complex levels did not change.
  
  
  CONCLUSIONS
  Small sample size.
  
  
  CONCLUSIONS
  Short-term fenofibrate administration not only improved lipid profiles, but also ameliorated insulin resistance, hypertension and oxidative stress markers in patients with metabolic syndrome, suggesting that fenofibrate can decrease the risk of arteriosclerosis through various pathways.
authors: Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200, Kiyotake, Miyazaki 889-1692, Japan. Electronic address:intron@med.miyazaki-u.ac.jp.
authors: Hiroaki
authors: H
authors: Ueno
authors: Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200, Kiyotake, Miyazaki 889-1692, Japan.
authors: Yukie
authors: Y
authors: Saitoh
authors: Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200, Kiyotake, Miyazaki 889-1692, Japan.
authors: Masanari
authors: M
authors: Mizuta
authors: Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200, Kiyotake, Miyazaki 889-1692, Japan.
authors: Tomomi
authors: T
authors: Shiiya
authors: Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200, Kiyotake, Miyazaki 889-1692, Japan.
authors: Kenji
authors: K
authors: Noma
authors: Ikagaku Co., Ltd., Kyoto, Japan.
authors: Shinichi
authors: S
authors: Mashiba
authors: Ikagaku Co., Ltd., Kyoto, Japan.
authors: Shiho
authors: S
authors: Kojima
authors: Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200, Kiyotake, Miyazaki 889-1692, Japan.
authors: Masamitsu
authors: M
authors: Nakazato